{"F": {"ts_code": "US.ANIP", "name": "ANI Pharmaceuticals", "mkt": "US", "ccy": "美元", "sw1": "专业与通用药品制造商", "sw2": "专业与通用药品制造商", "sw3": "", "ind": "专业与通用药品制造商", "fin_source": "futu", "market": "NASDAQ", "list_date": null, "is_fin": false, "roles": {"fin": false, "commodity": false, "precious": false, "regulated": false, "hard": false, "growth": false}, "province": null, "main_business": "", "introduction": "", "close": 71.23, "pe_ttm": 15.518, "pb": 2.738, "dv_ttm": 0.0, "total_mv": 163540.433024, "trade_date": "20260904", "years": ["最近年报"], "multi_year": false, "period": "最近年报", "gm_series": [61.4], "rev_series": [8.8], "np_series": [0.8], "roe_series": [14.9], "rev_ttm": 8.8, "np_ttm": 1.0, "ocf_ttm": 1.9, "fcf_ttm": null, "fcf_yield": null, "ocf_yield": 11.6, "gm_median": 61.4, "gm_std": null, "gm_stab": null, "gm_chg_2022": null, "npm_median": 8.9, "roe_median": 14.9, "commodity": false, "hard_ratio": 4.0, "fix_assets": 0.5, "hard_note": "PP&E 毛额 × 0.5 近似净额", "goodwill_ratio": null, "pb_calc": null, "capex_dep": null, "interest_debt": null, "debt_ebitda": null, "ebitda": 2.1, "debt_ratio": 62.5, "debt_mv": null, "payout": 0.0, "div_years": 0, "rev_cagr3": null, "np_cagr3": null, "rev_yoy": 43.8, "np_yoy": 522.9, "np_vol": null, "loss_years": 0, "far_share": 68.0, "earn_yield": 6.4, "consensus_n": 0, "fwd_pe": null, "fwd_pe2": null, "fwd_g1": null, "fwd_g2": null, "peg": null, "consensus_disp": null, "mainbz": [], "ret_prev_year": null, "ret_prev2_year": null, "ret_pivot": null, "prev_year": "", "prev2_year": "", "ret_ytd": -9.8, "ret_20": -9.0, "ret_60": -13.0, "ret_120": -1.3, "ret_250": -25.2, "mdd_250": null, "vol_250": null, "pos_52w": 71.6, "eps": 3.32}, "S": {"duration": 32, "pricing": 63, "hard": 6, "bondness": 13}, "label": "成长兑现", "tags": ["轻资产现金牛"], "text": {"像什么": ["盈利在追估值:最新净利润同比 523%,PE TTM 15.5 倍,历史 PEG(PE ÷ 最新增速)0.03。", "经营现金流 1.9 亿(正),没有一致预期数据,风险在增速能否延续。"], "为什么(不)算钱的替代品": "只占定价权一条(毛利率 61.4%),硬资产占比 4%。分子能跟上通胀,但没有重置成本对冲;按'定价权·品牌'看,不按硬资产看。", "加息期怎么走": "估值不靠远期故事,加息期比纯久期抗跌;风险在订单与增速,盯业绩不盯利率。", "四问": [["当前 FCF 能覆盖多少市值?", "经营现金流/市值 11.6%(futu 无资本开支,FCF 按经营现金流 × 0.7 近似)。覆盖高。"], ["能否每年提价而不掉量?", "毛利率最新年报 61.4%。能。"], ["资产重置成本随通胀涨吗?", "固定资产占总资产 4%。没有资产可言。"], ["估值里多少来自 5 年后的故事?", "按 PE 15.5 倍 粗算,约 68%(1 − 5/PE)。中等。"]], "价格行为": "近一年 -25%,现价在 52 周高点的 72%;近 20 / 60 / 120 日 -9% / -13% / -1%。", "行业对照": ["同富途行业「专业与通用药品制造商」85 家中位:PE 21.0 / 股息率 0.0% / 毛利率 54.9% / 固定资产占比 10% / 分红率 0%。", "ANI Pharmaceuticals:PE 比行业中位低 5.5倍;股息率 与行业中位持平;毛利率 比行业中位高 6.5个百分点;固定资产占比 比行业中位低 5.6个百分点。"]}}